UPDATE: ALTRAN TECHNOLOGIES : Altran launches new strategic

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
102
UPDATE: ALTRAN TECHNOLOGIES : Altran launches new strategic plan: The High Road, Altran 2022

This is an update of the announcement from 15:24 28.06.2018 CEST. Reason for the update:

Press release
 
  28.06.2018
         

Altran launches new strategic plan: The High Road, Altran 2022

  • The plan capitalizes on an attractive market, fueled by technology disruptions and digitalization across industries  
  • Building on seamless integration of Aricent, Altran assumes undisputed leadership, leverages a multi-industry footprint and a premier global delivery model  
  • Clients to benefit from both differentiating high-value services and R&D cost optimization  
  • Altran as a new league player, with enhanced growth profile, best-in-class financials, and delivering superior shareholder value

              

The High Road, Altran 2022 - STRATEGIC HIGHLIGHTS

  • Engineering and R&D services market to grow by c. 9% p.a. to €240bn by 2022 (2017: €155bn) with highly differentiated growth patterns across geographies and industries.
  • Altran to focus on high-tech, high-growth industries following Aricent acquisition Altran to leverage its leadership position and accelerate growth in North America , strengthen its number 1 position in Europe and pursue selective expansion in Asia
  • Altran to address differentiated clients' needs with distinct ER&D services models : mainstream engineering, high-value services and Industrialized GlobalShore©

The High Road, Altran 2022 - 2022 FINANCIAL TARGETS

  • Revenues : c. € 4.0 billion at constant perimeter
  • Operating margin : c. 14.5% [1]
  • Free cash Flow : c. 9% of revenues [2]
  • Leverage ratio : below 1.5x
  • Earnings per share : x2 (vs. reported 2017 of € 0.68/share)

London, June 28 , Altran, the global leader in Engineering and R&D services (ER&D), today unveiled The High Road, Altran 2022, a new five-year strategic plan to elevate its service model and expand its footprint in key industries and geographies to meet client demand and powerful technological disruptions. The plan was presented to investors at a Capital Markets Day held in London. The High Road, Altran 2022 will capitalize on the projected growth of the ER&D services market of c.9% per year between 2017 and 2022, from €155 billion in 2017 to €240 billion in 2022 with highly differentiated growth patterns across geographies and industries.

The ER&D market transformation is driven by:

  • an avalanche of technology disruptions, with unprecedented changes brought by digital, AI, connectivity and autonomisation.
  • the accelerated growth rate in hi-tech areas such as software, life sciences, semiconductors and automotive, reaching double-digit levels in the US and Asia;
  • the geographic mismatch in talent where currently, 60% of R&D budgets are spent in the US, Western Europe and Japan, while 20% of engineers graduate in these geographies;
  • and the shift in spending focus to industrialized and high-value services.

             

Dominique Cerutti, Chairman and Chief Executive Officer of the Altran Group , said: " With our new strategic plan, The High Road, Altran 2022, we will capitalize on the opportunities that lie ahead as client demand rapidly evolves. By expanding our footprint in fast-growing industries and geographies, and sharpening our service models, we will continue to elevate our growth profile while expanding our margins to new levels. Leveraging our first mover advantage, great talents and our extensive portfolio of services, we are positioned to become a preferred partner of the Top 1000 R&D global spenders with both high-value and R&D cost optimization services. We are delighted with the progress on the Aricent integration and client feedback; as we continue to execute we will deliver superior return to shareholders."

Three Strategic axes and four enablers for The High Road, Altran 2022 The High Road, Altran 2022 relies on three strategic axes:

  • Best-of-breed synergetic service models : Clients are now differentiating between (i) activities which truly create a competitive advantage for clients and other processes as well as between (ii) activities which have an immediate impact on their performance and those that do not. Altran will need to elevate its models to match the specific needs of each of these segments. High-value services will drive growth across the Group's portfolio of recognized brands in attractive domains such as Cambridge Consultants and Synapse in innovative product developments, frog in design, or the Group's portfolio of World Class Centers and software frameworks. Industrialized GlobalShore© will leverage the Group's Global Delivery Centers to seize global opportunities, offering clients access to global talents pools and cost competitiveness by increasing the number of near- and offshore engineers to 25,000 and focusing on industrialization.  
  • Focus on high-growth industries: Software and Internet, Semiconductor and Electronics, Automotive, Life Sciences and Next Gen Communications will add € 750m of revenues organically between 2017 and 2022. As some of these sectors morph into fundamental technology blocks enabling next gen innovations such as autonomous cars, the internet of things or 5G, they create significant opportunities across industries.
  • Geographic leadership : Demonstrate Altran's leadership position in North America by reaching Revenues of c.$ 1.2bn in the region in 2022, up from $ 800m in 2017, through the building of a leading-edge Software Product Engineering company and developing aggressively in the Automotive sector by leveraging synergies with Aricent; strengthen leading position in Europe with a focus on accelerated organic growth and will initiate a selective expansion program in Asia.

The Group has also highlighted four operational enablers supporting the execution of the strategic plan:

  • Convergence program: a phased and focused program de-risking the execution of the strategy, enabling synergy capture and preparing the deployment of a common target operating model between Altran and Aricent. 100-day after closing, the assumptions underpinning the path to success have been confirmed in terms of leadership stability, commercial pipeline building, operations efficiency as well as synergies that will be delivered.  
  • Organization: a sharpened organization focusing on execution within two zones: Europe and North America, supported by global industry leaders and Group transversal delivery, transformation, technology and innovation teams.  
  • Leadership bench: Altran has cultivated, including with the acquisition of Aricent, a leadership bench of very diverse and seasoned executives with complementary skills, business cultures and large scale operation transformation experiences which is unique in our industry.  
  • Operational excellence: The Group has reconfirmed operational excellence as a top priority and a lever for material margin improvement. It has appointed several Group Senior Executives focusing on operations and execution. One of the immediate priority will be to execute a profit turnaround in Germany. Altran has reinforced its German team and committed both Group and external resources to complete this turnaround.

       

2022 financial objectives: focus on profitable growth and deleveraging The deployment of The High Road, Altran 2022 strategic plan is expected to generate:

  • Revenues: c. € 4.0 billion at constant perimeter
  • Operating Margin: c. 14.5%
  • Free cash Flow (incl. financing costs) : c.9% of Revenues
  • Leverage ratio: 1.5x
  • Earnings per Share: x2 (vs. reported 2017 of € 0.68/share)

The Group will deploy its capital in a balanced way between shareholder value creation, reinvestment in the business, and taxes and financial commitments is anticipated:

  • The Group's financial policy will prioritize deleveraging , with the objective to be below 2.5x in 2020 and below 1.5x in 2022. This will be achieved by allocating the Free Cash Flow of the company to the gradual repayment of debt while maintain a cash balance above € 250m and remunerating shareholders in line with past practices.  
  • Strong drivers are supporting the expansion of the Group's Free Cash Flow : (i) the increase in the operating margin including through synergies and cost savings, a capital intensity around 2% of Revenues, while working capital requirements will be commensurate with growth; (ii) Financial costs are expected to decrease over time as debt is repaid, while the Aricent cash commitments will decrease each year and end in 2021, finally the tax structure will be revamped and the group should benefit from an improving tax environment.

From Ignition 2020 to The High Road 2022 Altran has reconfirmed that on a standalone basis the Group had been on a growth and margin improvement trajectory that would have led to the achievement of the targets of its previous plan, Altran 2020. Ignition .

A presentation for investors is available on the company's website

About Altran Altran ranks as the undisputed global leader in Engineering and R&D services (ER&D), following its acquisition of Aricent. The company offers clients an unmatched value proposition to address their transformation and innovation needs. Altran works alongside its clients, from initial concept through industrialization, to invent the products and services of tomorrow. For over 30 years, the company has provided expertise in aerospace, automotive, defense, energy, finance, life sciences, railway and telecommunications. The Aricent acquisition extends this leadership to semiconductors, digital experience and design innovation. Combined, Altran and Aricent generated revenues of €2.9 billion in 2017, with some 45,000 employees in more than 30 countries.

www.altran.com

Contacts

Stéphanie Bia Group Vice-President Investor Relations Tel: + 33 (0)1 46 41 72 01 stephanie.bia@altran.com

Marine Boulot Group Vice-President Communications Tel: + 33 (0)1 46 41 71 73 marine.boulot@altran.com

Follow us on Twitter: @Altran

DISCLAIMER This press release contains forward-looking statements (as defined in the United States Private Securities Litigation Reform Act, as amended) based upon current management expectations. Numerous risks, uncertainties and other factors (including, risks relating to: government legislation affecting our businesses; competition; our ability to manage rapid technological change in the industries in which we compete; litigation risks, labour issues; unanticipated costs from disposals or restructuring) may cause actual results to differ materially from those anticipated, projected or implied in or by the forward-looking statements. Many of the factors that will determine our future results are beyond our ability to control or predict. These forward-looking statements are subject to risks and uncertainties and, therefore, actual results may differ materially from our forward-looking statements. You should not place undue reliance on forward-looking statements which reflect our views only as of the date of this presentation. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

[1] Operating Margin is defined as Operating Income plus Amortization of intangibles assets arising from business combinations plus Non-recurring items plus Share-based compensation.

[2] Free Cash Flow (incl. financing costs) defined as Operating Margin plus Depreciation & Amortization (D&A), plus or minus the impact of Non-cash P&L, plus or minus the Cash impact on non-recurring, plus or minus the Decrease/increase of working capital, minus Tax paid, minus Capital expenditures net of fixed assets sale proceeds minus Cash financing costs.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 22

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 27

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading